CaLLing Targeted Therapies: Advancements in Chronic Lymphocytic Leukemia

<p>Mikhaila Rice, Pharm.D., BCPS (<a href='https://twitter.com/MikhailaPharmD'>@MikhailaPharmD</a>) reviews chronic lymphocytic leukemia diagnosis and historical treatment options, describes the pharmacology of Bruton tyrosine kinase inhibitors and venetoclax, and discusses the use of targeted agents as first line therapy for chronic lymphocytic leukemia.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>